Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MegaNatural-BP is a patented, water-extracted grape seed extract (GSE) developed by Polyphenolics, a division of Constellation Brands. It is characterized by a high concentration of low-molecular-weight polyphenols, specifically proanthocyanidins, which are standardized for optimal bioavailability. The extract's primary mechanism of action is the activation of endothelial nitric oxide synthase (eNOS) in the blood vessel lining. This activation leads to increased production of nitric oxide (NO), a potent vasodilator that relaxes arterial walls and improves blood flow. Clinical research, including studies conducted at the University of California, Davis, has demonstrated that MegaNatural-BP can significantly reduce both systolic and diastolic blood pressure in individuals with prehypertension and metabolic syndrome. Unlike many other grape seed extracts, it is produced from a specific blend of unfermented California wine grapes using a solvent-free process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MegaNatural-BP.